S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
His system isolated NVIDIA - Here's His Next Buy. (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
His system isolated NVIDIA - Here's His Next Buy. (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
His system isolated NVIDIA - Here's His Next Buy. (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
His system isolated NVIDIA - Here's His Next Buy. (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Forecast, Price & News

$0.61
0.00 (0.00%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.60
$0.63
50-Day Range
$0.51
$1.05
52-Week Range
$0.51
$4.37
Volume
377,861 shs
Average Volume
4.83 million shs
Market Capitalization
$116.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Reduce
1.80 Rating Score
Upside/​Downside
391.6% Upside
$3.00 Price Target
Short Interest
Healthy
3.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.31mentions of Nektar Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$26,174 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.00) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

176th out of 964 stocks

Pharmaceutical Preparations Industry

64th out of 439 stocks


NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Price History

NKTR Stock News Headlines

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Nektar Therapeutics Q2 Loss decreases, beats estimates
Howard Robin seeks another turnaround at Nektar
Jefferies upgrades Nektar Therapeutics (NKTR) to a Hold
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
216
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+391.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-349.75%
Pretax Margin
-346.47%

Debt

Sales & Book Value

Annual Sales
$87.74 million
Book Value
$1.95 per share

Miscellaneous

Free Float
184,282,000
Market Cap
$116.01 million
Optionable
Optionable
Beta
1.00

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 70)
    CEO, Pres & Director
    Comp: $1.83M
  • Mr. Mark A. Wilson (Age 51)
    Sr. VP, Chief Legal Officer & Sec.
    Comp: $749.99k
  • Dr. Jonathan Zalevsky Ph.D. (Age 48)
    Sr. VP & Chief R&D Officer
    Comp: $1.25M
  • Ms. Sandra A. Gardiner (Age 57)
    Chief Financial Officer
  • Vivian Wu
    Director of Investor Relations & Corp. Affairs
  • Mr. Robert Bacci
    Sr. VP of HR & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Bus. Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 57)
    M.D., Chief Medical Officer
  • Dr. Loui T. Madakamutil
    VP and Head of Discovery & Research













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" NKTR shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2023?

5 brokers have issued 12-month price objectives for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $1.00 to $6.00. On average, they anticipate the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 391.6% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 on January 1st, 2023. Since then, NKTR stock has decreased by 73.0% and is now trading at $0.6102.
View the best growth stocks for 2023 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03. The biopharmaceutical company earned $20.50 million during the quarter, compared to analyst estimates of $20.94 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 67.03% and a negative net margin of 349.75%. During the same quarter in the prior year, the business posted ($0.85) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Deep Track Capital LP (9.45%), Monaco Asset Management SAM (4.89%), BlackRock Inc. (4.55%), Acadian Asset Management LLC (2.32%), Renaissance Technologies LLC (2.16%) and Assenagon Asset Management S.A. (1.10%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $0.61.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $116.01 million and generates $87.74 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 216 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -